# RxSight, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/RxSight, Inc.). ## Overview RxSight, Inc. is a U.S.-based medical technology company focused on cataract surgery. Its proprietary RxSight system combines the Light Adjustable Lens with a Light Delivery Device and related accessories to let surgeons adjust a patient’s lens power after implantation. The company operates through a commercial organization and subsidiaries in Hong Kong and Europe to support sales and expansion outside the United States. ## Products & services • RxSight Light Adjustable Lens (LAL/LAL+) • RxSight Light Delivery Device (LDD) • Post-surgery lens adjustment procedures • Related accessories, service, and training • Clinical education and customer support - **Light Adjustable Lenses** (65%) — Premium intraocular lenses implanted during cataract surgery and later adjusted with UV light. - **Light Delivery Devices** (20%) — Capital devices installed in practices to deliver the light used to adjust the lens after surgery. - **Accessories and consumables** (10%) — Ancillary items used with the lens and device during treatment and follow-up. - **Service and warranty** (5%) — Installation, training, warranty, and ongoing service tied to the LDD base. - RxSight Light Adjustable Lens (LAL/LAL+) - RxSight Light Delivery Device (LDD) - Post-surgery lens adjustment procedures - Related accessories, service, and training - Clinical education and customer support ## Customers RxSight sells primarily to ophthalmic practices and ambulatory surgery centers involved in cataract surgery. Practices buy the LDD to enable postoperative lens adjustments, while surgery centers buy the LAL for implantation in premium cataract procedures. The end users are cataract surgeons and their patients, with adoption driven by the desire for more precise refractive outcomes and reduced dependence on glasses. - **Ophthalmic practices** (primary) — Buy LDD systems, training, and support to perform postoperative lens adjustments and grow premium cataract volume. - **Ambulatory surgery centers** (primary) — Buy LALs used in cataract procedures and participate in premium IOL workflows. - **Cataract surgeons** (primary) — Use the system to customize refractive outcomes after surgery and improve patient satisfaction. - **Patients undergoing cataract surgery** (secondary) — Ultimately receive the implanted lens and adjustment process, seeking better visual outcomes. - **International distributors and healthcare providers** (emerging) — Support selective non-U.S. commercialization in approved markets. - Ophthalmic practices buy LDDs to support postoperative adjustments - Ambulatory surgery centers buy LALs for cataract implantation - Cataract surgeons adopt the system to improve refractive precision - Patients seek premium cataract outcomes and potential glasses independence - Clinical staff and practice managers need training and workflow support ## Geography RxSight primarily generates revenue in the United States, where it focuses its commercial organization and installed base. The company also has approvals in Europe, Canada, Mexico, Singapore, Australia, and South Korea, with subsidiaries in Hong Kong and the Netherlands plus operations in the UK and Germany. International markets are strategically important because premium cataract procedures are larger outside the U.S., but reimbursement and regulatory pathways vary by country. - **United States** (90%) — Primary commercial focus and main source of product sales - **International** (10%) — Approved markets and supporting subsidiaries; near-term sales expected to be limited - United States is the core commercial market and main revenue source - Europe, Canada, Mexico, Singapore, Australia, and South Korea are approved markets - Hong Kong and Netherlands subsidiaries support international operations - UK branch and German subsidiary extend European presence - Non-U.S. reimbursement rules vary and affect adoption speed ## Strategy RxSight’s strategy centers on expanding adoption of the Light Adjustable Lens system, increasing the installed base of Light Delivery Devices, and strengthening clinical and commercial support for surgeons and practices. The company is also investing in product enhancements, broader indications, manufacturing improvements, and selective international expansion to widen the addressable market. These priorities are designed to make the system easier to adopt, improve outcomes, and deepen utilization within existing accounts. - **Grow LAL adoption and utilization** (short-term) — Higher lens utilization drives recurring procedure volume and deepens account penetration. - **Expand the LDD installed base** (medium-term) — More installed devices create a larger footprint for future LAL usage and service revenue. - **Enhance the product platform** (medium-term) — Software, lens, and manufacturing improvements can improve outcomes and adoption. - **Selective international expansion** (long-term) — Approved foreign markets broaden the long-term addressable market beyond the U.S. - Increase LAL adoption in existing and new accounts - Expand the installed base of LDD systems - Improve clinical outcomes and customer experience - Broaden indications and patient eligibility - Pursue selective international commercialization ## Risks RxSight depends on adoption of a specialized surgical workflow, regulatory approvals, and effective training of doctors and practice staff. The business also relies on third-party and single-source suppliers for certain components, and its intellectual property and trade secrets are central to its competitive position. As a medical device company, it faces product safety, reimbursement, competition, and commercialization risks that can slow penetration or affect customer confidence. - **Regulatory approval delays or denials** [high] — Commercialization and new indications depend on maintaining and expanding clearances in multiple jurisdictions. - **Supply chain concentration** [high] — Dependence on third parties and single/sole source suppliers can disrupt production and raise costs. - **Slow adoption of a new surgical workflow** [medium] — Doctors must learn a new procedure and train staff, which can limit penetration versus conventional IOLs. - **Intellectual property leakage or invalidation** [high] — The system depends on proprietary lens material, device design, and trade secrets. - **Competition in premium IOLs** [medium] — Alternative lenses and surgical technologies can limit market share and pricing power. - Regulatory approvals are required for current and future products - Single-source suppliers can create component shortages or price pressure - Adoption depends on surgeon training and workflow change - IP protection is critical to preserve exclusivity and differentiation - Product safety or satisfaction issues could slow market penetration ## Accounting Revenue recognition is a key accounting area because RxSight sells a mix of consumable lenses, capital devices, training, service, and accessories with different timing rules. LAL revenue is recognized when implantation is reported, while LDD revenue is recognized at installation and acceptance, and service/warranty revenue is recognized over time. Consignment inventory, bundled device contracts, and estimates around warranties, stock compensation, and potential impairment judgments can all affect reported results. - **Revenue recognition by product type** — Point-in-time vs over-time recognition - **Consignment inventory** — Timing of product revenue - **Bundled LDD arrangements** — Revenue allocation and deferral - **Warranty and service estimates** — Gross margin and liabilities - **Stock-based compensation** — Operating expense and dilution - LAL revenue is recognized when the lens is implanted - LDD contracts include multiple obligations with different timing - Service and warranty revenue is recognized ratably over the service period - Consignment inventory affects timing of product revenue - Stock compensation and estimates can affect operating expenses --- *Last updated: 2026-04-29T04:54:17.093797+00:00*